将ALBI等级与老年营养风险指数相结合,提高了肝细胞癌风险分层
Heechul Nam1,2, Pil Soo Sung1,2, Sung Won Lee1,2
1Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Liver cancer
|April 21, 2025
概括
根据老年营养风险指数 (GNRI) 评估的营养状况显著影响肝细胞癌 (HCC) 患者的整体生存期. 将GNRI与白蛋白-白素 (ALBI) 等级相结合,可以改善HCC的预后分层.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 老年医学 老年医学
背景情况:
- 营养状况是肝细胞癌 (HCC) 的关键预后因素,但在临床评估中经常被忽视.
- 老年营养风险指数 (GNRI) 是评估老年人营养状况的有效工具.
研究的目的:
- 调查GNRI和HCC患者的整体存活率 (OS) 之间的关联.
- 评估将GNRI与白蛋白-白素 (ALBI) 等级集成的潜力,以提高HCC的预后分层.
主要方法:
- 对16,416名未接受过治疗的HCC患者的全国性注册数据集 (韩国中央癌症注册,2008-2019) 的分析.
- 使用受限立方脊柱回归来评估GNRI与生存之间的关联,按ALBI等级分层.
- 评估了GNRI和ALBI等级在不同巴塞罗那诊所肝癌 (BCLC) 阶段的综合预后值.
主要成果:
- 总生存期 (中位数为3.1年) 受ALBI等级和GNRI的综合评估 (p <0.001) 的显著影响.
- 综合风险分层显示,在BCLC0/A,B和C阶段 (所有p < 0.001),但不是D阶段 (p = 0.082) 中与OS有显著的相关性.
- 在多变量分析中,有利的ALBI等级和高的GNRI得分分别与死亡风险降低有关.
结论:
- 在各种ALBI等级和BCLC阶段,GNRI与HCC患者的OS显著相关.
- 将GNRI集成到ALBI分级系统中提供了一种有希望的方法来改善HCC患者的风险分层.
- 这种综合方法可能有助于个性化治疗策略和改善患者的治疗结果.
相关概念视频
01:22Bioavailability: Influencing Factors
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...